FEV-话题@MedSci

#FEV#

20篇内容 | 1106人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2058469, encodeId=32282058469b5, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, objectTitle=科普：什么是番茄流感/番茄热（Tomato flu/Tomato Fever）？, objectType=article, longId=726828, objectId=2c7ee2682886, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c7ee2682886, replyNumber=0, likeNumber=75, createdTime=2022-11-04, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c7ee2682886, moduleTitle=科普：什么是番茄流感/番茄热（Tomato flu/Tomato Fever）？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c7ee2682886)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058470, encodeId=636e20584e08b, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, objectTitle=Radiology：利用胸片的深度学习模型预测COPD患者生存率优于FEV1, objectType=article, longId=729127, objectId=42dbe29127f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42dbe29127f3, replyNumber=0, likeNumber=81, createdTime=2022-07-31, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42dbe29127f3, moduleTitle=Radiology：利用胸片的深度学习模型预测COPD患者生存率优于FEV1, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42dbe29127f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058468, encodeId=ef672058468f5, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, objectTitle=英国NICE批准Ofev用于间质性肺病 (ILD) , objectType=article, longId=218850, objectId=0ad32188503c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ad32188503c, replyNumber=0, likeNumber=108, createdTime=2022-09-07, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ad32188503c, moduleTitle=英国NICE批准Ofev用于间质性肺病 (ILD) , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ad32188503c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058467, encodeId=2f13205846e11, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, objectTitle=Eur Respir J：COPD患者FEV1加速下降与心血管疾病和死亡风险的关系, objectType=article, longId=201302, objectId=a948201302da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a948201302da, replyNumber=0, likeNumber=83, createdTime=2021-03-04, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a948201302da, moduleTitle=Eur Respir J：COPD患者FEV1加速下降与心血管疾病和死亡风险的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a948201302da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058466, encodeId=4a21205846674, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, objectTitle=诺华在III期临床失败后，放弃其口服哮喘药物fevipiprant, objectType=article, longId=184902, objectId=8f0518490243, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f0518490243, replyNumber=0, likeNumber=74, createdTime=2020-08-31, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f0518490243, moduleTitle=诺华在III期临床失败后，放弃其口服哮喘药物fevipiprant, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f0518490243)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058465, encodeId=6e822058465cd, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, objectTitle=加拿大卫生部批准OFEV（nintedanib）用以缓解系统性硬化症相关ILD患者肺功能下降, objectType=article, longId=183715, objectId=fe2f183e1514, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe2f183e1514, replyNumber=0, likeNumber=65, createdTime=2020-10-25, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe2f183e1514, moduleTitle=加拿大卫生部批准OFEV（nintedanib）用以缓解系统性硬化症相关ILD患者肺功能下降, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe2f183e1514)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058464, encodeId=c93920584644a, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, objectTitle=勃林格殷格翰的多途径激酶抑制剂Ofev治疗慢性纤维化间质性肺病，获得FDA的突破性治疗指定, objectType=article, longId=181137, objectId=82d718113e9c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82d718113e9c, replyNumber=0, likeNumber=75, createdTime=2019-10-25, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82d718113e9c, moduleTitle=勃林格殷格翰的多途径激酶抑制剂Ofev治疗慢性纤维化间质性肺病，获得FDA的突破性治疗指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82d718113e9c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058463, encodeId=959320584638a, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, objectTitle=JAMA：FEV1/FVC与COPD相关不良事件风险, objectType=article, longId=173294, objectId=2ade1e3294e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ade1e3294e5, replyNumber=0, likeNumber=93, createdTime=2019-12-24, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ade1e3294e5, moduleTitle=JAMA：FEV1/FVC与COPD相关不良事件风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ade1e3294e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058462, encodeId=ada62058462ff, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, objectTitle=BI：Ofev®（nintedanib，尼达尼布）治疗特发性肺纤维化表现出持续长期疗效, objectType=article, longId=122647, objectId=9b3f12264ea6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b3f12264ea6, replyNumber=0, likeNumber=79, createdTime=2018-06-10, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b3f12264ea6, moduleTitle=BI：Ofev®（nintedanib，尼达尼布）治疗特发性肺纤维化表现出持续长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b3f12264ea6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058460, encodeId=383020584605f, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, objectTitle=Chest：降低COPD恶化风险与FEV1的改善相关！, objectType=article, longId=98568, objectId=0a769856893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a769856893, replyNumber=0, likeNumber=68, createdTime=2017-08-09, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a769856893, moduleTitle=Chest：降低COPD恶化风险与FEV1的改善相关！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a769856893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058459, encodeId=1de7205845974, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, objectTitle=CHEST：FEV1的改善与减少COPD急性加重密切相关！, objectType=article, longId=98445, objectId=d7fe9844504, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7fe9844504, replyNumber=0, likeNumber=75, createdTime=2017-06-19, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7fe9844504, moduleTitle=CHEST：FEV1的改善与减少COPD急性加重密切相关！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7fe9844504)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058461, encodeId=c0c6205846184, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, objectTitle=Am J Hum Genet：细胞信号传导介质β-catenin缺陷导致FEVR的视网膜血管病变！, objectType=article, longId=100652, objectId=124d10065220, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=124d10065220, replyNumber=0, likeNumber=134, createdTime=2018-03-22, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=124d10065220, moduleTitle=Am J Hum Genet：细胞信号传导介质β-catenin缺陷导致FEVR的视网膜血管病变！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=124d10065220)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058456, encodeId=3ea9205845671, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, objectTitle=Lancet Respir Med：前列腺素D2受体拮抗剂Fevipiprant，治疗中重度难治性哮喘, objectType=article, longId=77285, objectId=e129e728598, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e129e728598, replyNumber=0, likeNumber=74, createdTime=2017-05-24, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e129e728598, moduleTitle=Lancet Respir Med：前列腺素D2受体拮抗剂Fevipiprant，治疗中重度难治性哮喘, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e129e728598)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058455, encodeId=0ac620584557a, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, objectTitle=ESH 2016：我国FEVER研究亚组分析：早期血压达标，患者获益更大, objectType=article, longId=70862, objectId=e931e0862f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e931e0862f2, replyNumber=0, likeNumber=88, createdTime=2017-02-13, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e931e0862f2, moduleTitle=ESH 2016：我国FEVER研究亚组分析：早期血压达标，患者获益更大, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e931e0862f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058458, encodeId=c5ad2058458da, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, objectTitle=Chest：肺功能FEV1 <30％的成人囊性纤维化患者的生存现状分析, objectType=article, longId=88640, objectId=14c3886402d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14c3886402d, replyNumber=0, likeNumber=77, createdTime=2017-11-07, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14c3886402d, moduleTitle=Chest：肺功能FEV1 <30％的成人囊性纤维化患者的生存现状分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14c3886402d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058457, encodeId=5f19205845eb1, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, objectTitle=勃林格血管激酶抑制剂Ofev（nintedanib）在欧美喜获治疗系统性硬化症（SSc）的孤儿药地位, objectType=article, longId=77494, objectId=d3b3e749422, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3b3e749422, replyNumber=0, likeNumber=99, createdTime=2017-03-04, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3b3e749422, moduleTitle=勃林格血管激酶抑制剂Ofev（nintedanib）在欧美喜获治疗系统性硬化症（SSc）的孤儿药地位, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3b3e749422)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058453, encodeId=345420584539f, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, objectTitle=NEJM：FEV1的加速下降并不是慢性阻塞性肺疾病的专性特征, objectType=article, longId=53104, objectId=bceb53104b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bceb53104b0, replyNumber=0, likeNumber=74, createdTime=2016-02-10, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bceb53104b0, moduleTitle=NEJM：FEV1的加速下降并不是慢性阻塞性肺疾病的专性特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bceb53104b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058454, encodeId=4e2b205845487, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, objectTitle=NEJM：COPD患者一生中FEV1下降的速度变化很大, objectType=article, longId=53205, objectId=73e853205b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73e853205b1, replyNumber=0, likeNumber=89, createdTime=2015-10-15, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73e853205b1, moduleTitle=NEJM：COPD患者一生中FEV1下降的速度变化很大, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73e853205b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058452, encodeId=0df02058452a0, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, objectTitle=勃林格特发性肺纤维化药物Ofev欧盟监管收获好消息, objectType=article, longId=43227, objectId=34db4322e10, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34db4322e10, replyNumber=0, likeNumber=75, createdTime=2015-09-12, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34db4322e10, moduleTitle=勃林格特发性肺纤维化药物Ofev欧盟监管收获好消息, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34db4322e10)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058451, encodeId=812e205845150, content=<a href='/topic/show?id=1b69e363bb' target=_blank style='color:#2F92EE;'>#FEV#</a>, objectTitle=FDA批准Ofev对于特发性肺纤维化的治疗, objectType=article, longId=41844, objectId=39c94184460, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39c94184460, replyNumber=0, likeNumber=86, createdTime=2015-02-23, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39c94184460, moduleTitle=FDA批准Ofev对于特发性肺纤维化的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39c94184460)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FEV

2020-05-29

circumcision (审核中...)

前往app查看评论内容

#FEV#

科普：什么是番茄流感/番茄热（Tomato flu/Tomato Fever）？

2022-11-04

circumcision (审核中...)

前往app查看评论内容

#FEV#

Radiology：利用胸片的深度学习模型预测COPD患者生存率优于FEV1

2022-07-31

circumcision (审核中...)

前往app查看评论内容

#FEV#

英国NICE批准Ofev用于间质性肺病 (ILD)

2022-09-07

circumcision (审核中...)

前往app查看评论内容

#FEV#

Eur Respir J：COPD患者FEV1加速下降与心血管疾病和死亡风险的关系

2021-03-04

circumcision (审核中...)

前往app查看评论内容

#FEV#

诺华在III期临床失败后，放弃其口服哮喘药物fevipiprant

2020-08-31

circumcision (审核中...)

前往app查看评论内容

#FEV#

加拿大卫生部批准OFEV（nintedanib）用以缓解系统性硬化症相关ILD患者肺功能下降

2020-10-25

circumcision (审核中...)

前往app查看评论内容

#FEV#

勃林格殷格翰的多途径激酶抑制剂Ofev治疗慢性纤维化间质性肺病，获得FDA的突破性治疗指定

2019-10-25

circumcision (审核中...)

前往app查看评论内容

#FEV#

JAMA：FEV1/FVC与COPD相关不良事件风险

2019-12-24

circumcision (审核中...)

前往app查看评论内容

#FEV#

BI：Ofev®（nintedanib，尼达尼布）治疗特发性肺纤维化表现出持续长期疗效

2018-06-10

circumcision (审核中...)

前往app查看评论内容

#FEV#

Chest：降低COPD恶化风险与FEV1的改善相关！

2017-08-09

circumcision (审核中...)

前往app查看评论内容

#FEV#

CHEST：FEV1的改善与减少COPD急性加重密切相关！

2017-06-19

circumcision (审核中...)

前往app查看评论内容

#FEV#

Am J Hum Genet：细胞信号传导介质β-catenin缺陷导致FEVR的视网膜血管病变！

2018-03-22

circumcision (审核中...)

前往app查看评论内容

#FEV#

Lancet Respir Med：前列腺素D2受体拮抗剂Fevipiprant，治疗中重度难治性哮喘

2017-05-24

circumcision (审核中...)

前往app查看评论内容

#FEV#

ESH 2016：我国FEVER研究亚组分析：早期血压达标，患者获益更大

2017-02-13

circumcision (审核中...)

前往app查看评论内容

#FEV#

Chest：肺功能FEV1 <30％的成人囊性纤维化患者的生存现状分析

2017-11-07

circumcision (审核中...)

前往app查看评论内容

#FEV#

勃林格血管激酶抑制剂Ofev（nintedanib）在欧美喜获治疗系统性硬化症（SSc）的孤儿药地位

2017-03-04

circumcision (审核中...)

前往app查看评论内容

#FEV#

NEJM：FEV1的加速下降并不是慢性阻塞性肺疾病的专性特征

2016-02-10

circumcision (审核中...)

前往app查看评论内容

#FEV#

NEJM：COPD患者一生中FEV1下降的速度变化很大

2015-10-15

circumcision (审核中...)

前往app查看评论内容

#FEV#

勃林格特发性肺纤维化药物Ofev欧盟监管收获好消息

2015-09-12

医者仁心 (审核中...)

前往app查看评论内容

#FEV#

FDA批准Ofev对于特发性肺纤维化的治疗

2015-02-23

科室
- - 订阅+
  - 更多科室
工具
服务